AMGNAmgenRunning, no new patients
Study of Blinatumomab Administration in Chinese Pediatric Participants With Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
B Precursor Acute Lymphoblastic Leukemia · Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
3 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 2
- Patients
- 18 (final count)
- Started
- Jul 23, 2024
- Main results expected
- Jan 6, 2026
- Fully finished
- Oct 14, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of Participants with Complete Remission (CR)
Measured over: Up to 84 days
Number of Participants with CR with Partial Recovery of Peripheral Blood Counts (CRh)
Measured over: Up to 84 days
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT06054113 · record last updated 2026-11-02 · checked 2026-11-09 15:47 UTC